30 closest matches · ranked by relevance
Stage I Chronic Lymphocytic Leukemia · Stage II Chronic Lymphocytic Leukemia · Stage III Chronic Lymphocytic Leukemia
Primary: Rate of Confirmed MRD-negative Response — 0 proportion of patients
Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within 4 Cycles of Treatment — 80.0 percentage of participants — p=0.0000
Multiple Myeloma
Primary: Rate of Stringent Complete Response — 1 Participants
B-cell Acute Lymphoblastic Leukemia
Primary: Percentage of Participants With a Minimal Residual Disease (MRD) Response Within the First Treatment Cycle — 77.0 percentage of participants
Multiple Myeloma
Primary: The Percent of Patients With Minimal Residual Disease (MRD) Status Changing to Negative at Day 100 (Post-AHCT), Among Patients With MRD Positive at the End of Induction…
Multiple Myeloma
Primary: Percentage of Patients With MRD(-) Remissions at the Completion of Consolidation Therapy — 81.4 percentage of patients achieving MRD (-)
Chronic Lymphocytic Leukemia
Primary: Improvement in Quality of Remission: Number of Participants With Response Versus No Response by NCI Working Group Criteria Disease Status Change at Start/End of…
Chronic Lymphocytic Leukemia (CLL)
Primary: Complete Response — 45 Percentage of Participants
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Chronic Myeloid Leukemia · Minimal Residual Disease
Primary: Response: One Log Decrease in BCR-ABL — 3; 7 Participants
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
Alkylating Agent-Related Acute Myeloid Leukemia · Secondary Acute Myeloid Leukemia
Primary: Relapse-free Survival (RFS) — 21.5 Months
Acute Myeloid Leukemia
Primary: Percentage of Participants With Complete Remission or Complete Remission With Incomplete Recovery Blood Counts — 11 percentage of participants
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Plasma Cell Myeloma · Residual Disease
Primary: Percentage of Participants With MRD Negativity — 18; 31 percentage of participants
Multiple Myeloma
Primary: Number of Participants With MRD Negativity by the Completion of 6 Months of Daratumumab Therapy — 6; 4 Participants
CHRONIC MYELOGENOUS LEUKEMIA
Primary: Rate of Confirmed Best Cumulative Complete Molecular Response (CMR) — 13; 6; 91; 97 Participants — p=0.1083
Multiple Myeloma
Primary: Fraction of Patients (n=3) for Whom a sdAb Could be Generated That Binds to the Idiotype of the Paraprotein. — 2 Participants
Leukemia, Lymphocytic, Acute
Primary: Complete Response (CR) Rate — 28 percentage of participants
Multiple Myeloma
Primary: Overall Response Rate (ORR) — 1; 1; 7; 1 participants
Lymphocytic Leukemia · Mantle Cell Lymphoma
Primary: Overall Response Rate (ORR) — 61 percentage of participants
Multiple Myeloma
Primary: Primary Analysis: Overall Minimal Residual Disease (MRD) Negative Rate — 35.4; 53.3 Percentage of participants — p==0.0004
Adult Acute Megakaryoblastic Leukemia (M7) · Adult Acute Minimally Differentiated Myeloid Leukemia (M0) · Adult Acute Monoblastic Leukemia (M5a)
Primary: Achievability of Performing Individualized Drug Screening and Initiating Therapy Based on the Results of the Drug Screen for Poor Risk Patients With Relapsed or…
Relapsed or Refractory Mantle Cell Lymphoma (MCL)
Primary: Objective Response Rate (CR + PR) — 46.7 percentage of participants
Lymphoma · Hodgkin Disease · Lymphoma, Non-Hodgkin
Primary: 68Ga-DOTANOC Uptake in Lymphomas With PET/CT — 3.1 Standardized Uptake Value
Melanoma
Primary: Ganglioside Expressed by Tumor Cells (GD2) — 3; 3; 3; 3 Participants
Bone Marrow Failure Syndromes · Immunodeficiencies · Immune Dysregulation Syndromes
Primary: Number of Participants With Engraftment — 2 Participants
Multiple Myeloma
Primary: Overall Survival (OS)
Chronic Myeloid Leukemia
Primary: Percentage of Participants With Deep Molecular Response MR4.5 at 24 Months of Study Treatment — 35.3 Percentage of participants